In particular, genetic or pharmacological blockade of CB1R function has been shown to ameliorate various physiological processes associated with peripheral neuropathy, retinopathy, atherosclerosis, middle cerebral artery, and cardiac dysfunction in adults and in fetuses at the second half of gestation (Lupica et al. This evidence concerns the gene CNR1 and peripheral neuropathy.